Volume 8, Number 8—August 2002
Research
Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus
Yehuda Carmeli*†
, George M. Eliopoulos*†, and Matthew H. Samore*†
, George M. Eliopoulos*†, and Matthew H. Samore*†
Table 3
The effect of antibiotic treatment as risk factor for vancomycin-resistant enterococci
| Cases (%) | Control (%) | Unadjusted effect | Adjusted for explanatory modela | Adjusted for model and other antibioticsa | ||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic agent |
(233) |
(647) |
OR |
p
value |
OR
(95% CI) |
p
value |
OR
(95% CI) |
p
value |
| Penicillins | 67 (29) | 134 (21) | 1.5 | 0.04 | .99 (.63 to 1.6) | 0.97 | 1.0(.64 to 1.7) | 0.86 |
| β-lactam-inhibitor combination | 49 (21) | 98 (15) | 1.5 | 0.07 | .94 (.6 to 1.5) | 0.78 | ||
| Cephalosporins | 104 (45) | 248 (38) | 1.2 | 0.28 | 1.5 (1.0 to 2.4) | 0.048 | ||
| Third generation | 69 (30) | 97 (15) | 2.6 | <0.001 | 2.8 (1.7 to 4.5) | <0.001 | 2.8 (1.7 to 4.8) | <0.001 |
| Vancomycin (p.o.) | 4 (1.7) | 7 (1.1) | 1.2 | 083 | 1.0 (.25 to 4.2) | 0.96 | ||
| Vancomycin (i.v.) | 67 (29) | 121 (19) | 1.7 | 0.016 | 1.4 (.89 to 2.3) | 0.19 | .99 (.57 to 1.7) | 0.98 |
| Metronidazole (p.o.) | 13 (5.6) | 23 (3.6) | 1.5 | 0.29 | 1.0 (.42 to 2.5) | 0.97 | ||
| Metronidazole (i.v.) | 47 (20) | 57 (9) | 2.5 | <0.001 | 2.3 (1.3 to 3.9) | 0.003 | 2.1 (1.2 to 3.7) | 0.008 |
| Clindamycin | 20 (8.6) | 51 (7.9) | 1 | 0.9 | 1.5 (.76 to 2.8) | 0.26 | 1.1 (.55 to 2.3) | 0.76 |
| Quinoloneb | 48 (21) | 68 (11) | 2 | 0.005 | 1.6 (.94 to 2.6) | 0.086 | 1.5 (.85 to 2.6)b | 0.17b |
| Imipenem | 19 (8.2) | 27 (4.2) | 1.7 | 0.12 | 1.3 (.61 to 2.9) | 0.47 | 1.2 (.52 to 2.8) | 0.66 |
aAdjusted for the explanatory model detailed in Table 2.
b When included as a continuous variable (number of days of treatment with quinolone) OR=1.03, p=0.05.
OR, odds ratio; p.o., orally; i.v., intravenously.
Page created: July 16, 2010
Page updated: July 16, 2010
Page reviewed: July 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.